What is Hillstar Bio?
Hillstar Bio operates at the intersection of immunology and biotechnology, focusing on the selective depletion of pathogenic immune cells. Unlike conventional therapies that often rely on broad immunosuppression—which can leave patients vulnerable to secondary infections—Hillstar Bio utilizes a targeted approach to reset the immune system. This mechanism of action is designed to address the underlying pathology of autoimmune conditions while preserving healthy immune function. By focusing on high-precision therapeutic development, the company is addressing a critical gap in the current treatment landscape, aiming to provide long-term relief for patients suffering from chronic, debilitating conditions.
How much funding has Hillstar Bio raised?
Hillstar Bio has raised a total of $67M across 1 funding round:
Series A
$67M
Series A (2025): $67M with participation from LifeArc Ventures, Droia, Novo Holdings, Frazier Life Sciences Management, and Hummingbird Bioscience
Key Investors in Hillstar Bio
LifeArc Ventures
A medical research charity-backed venture firm that provides scientific insight and commercial support to early-stage life science companies.
Droia
A specialist investment firm dedicated to backing high-impact life science companies focused on saving patient lives.
Novo Holdings
A Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focusing on long-term life science investments.
What's next for Hillstar Bio?
With this major strategic investment, Hillstar Bio is well-positioned to accelerate its clinical development pipeline and scale its research operations. The company will likely prioritize the advancement of its lead candidates through rigorous clinical trials, aiming to validate its immune-reset platform in human subjects. Furthermore, the influx of capital will enable the expansion of its internal R&D capabilities and the potential for strategic partnerships to enhance its drug discovery engine. As the company transitions from early-stage development to a more mature clinical-stage entity, the focus will remain on achieving key regulatory milestones and demonstrating the long-term efficacy of its precision-targeted therapies in the competitive biotechnology market.
See full Hillstar Bio company page
